Quigley Reports Results For Phase IIb Study Of QR-333

Quigley has reported the results from its phase IIb double-blind, placebo-controlled, study of topical compound QR-333. It is intended for the treatment of symptomatic diabetic peripheral neuropathy.

The study reveals that the compound is safe and well tolerated. There were no statistical differences between active and placebo groups for the primary and secondary endpoints, measuring efficacy by the reduction of pain, symptomatic improvements, improved quality of life and improved sleep.

Reportedly, the company will continue to consider licensing, partnering or collaborative relationship opportunities, to further the development and potential commercialization of the QR-333 candidate and other formulations.

Ted Karkus, CEO of Quigley, said: We have recently hired an independent consultant to conduct a thorough review of the entire research and development portfolio of potential products in the Quigley pipeline. We will wait for this review to be completed before determining the next steps in the development of QR-333 and other formulations.